INTRODUCTION
A sthma is a common, chronic disorder of the airways that involves a complex interaction of airflow obstruction, bronchial hyperresponsiveness, and underlying inflammation with increased airway responsiveness to a variety of stimuli being typical. [1] [2] [3] [4] [5] Work-related asthma (WRA) includes both asthma of an occupational origin (occupational asthma [OA] ) and work-exacerbated asthma (WEA). OA includes sensitizer-induced asthma, resulting from sensitization to an antigen in the workplace, and irritant-induced asthma, induced by workplace exposures to irritants (Table 1) . Each condition has the potential for considerable acute morbidity, long-term disability, and adverse impact on income and quality of life. [6] [7] [8] [9] [10] [11] [12] The most common form of occupational lung disease in many industrialized countries, with approximately 10% to 15% of all prevalent adult cases attributed to occupational factors, 6 -8,10,12-14 OA is further classified into OA with latency or OA without latency. OA without latency is less common, and is believed to represent 5% to 15% of all OA cases. 1, 15 The percentage of new-onset adult asthma attributable to occupational causes is considered to be much higher, up to a third of all cases. 16, 17 The frequency of WEA, defined as preexisting reactive airways disease that is made temporarily or permanently worse due to occupational exposures, is substantially more common than OA. 18 The predisposing factors for developing OA with latency are not well known. Atopy is the primary established risk factor, operating largely with respect to high molecular weight (HMW) antigens such as animal proteins. It has been proposed that human leukocyte antigen class-2 alleles may be a risk factor for the development of OA resulting from low molecular weight agents. 11, 19, 20 Medical management and compensation decisions require a thorough assessment of suspected OA, which may be mistaken for non-OA unless a detailed history, including occupational history, and appropriate medical tests are performed to support an association with work. 21 
GUIDELINE FOCUS/TARGET POPULATION
The American College of Occupational and Environmental Medicine (ACOEM) created its evidence-based Work-related Asthma Guideline to primarily address diagnostic options to help determine whether an employee has asthma, and whether the asthma is related to workplace exposures (Fig. 1) The primary target population is working-age adults, although the literature searches included articles addressing all adults. Thus, it is recognized that the principles may apply more broadly.
GUIDELINE DEVELOPMENT PROCESS
A detailed methodology document specified evidence selection, scoring, incorporation of cost considerations, and formulation of recommendations. 22, 23 The aim was to identify the highest quality evidence on any given topic. Guidance was drafted using tables that abstracted the evidence and which were forwarded to the multidisciplinary Panel that reviewed the evidence and finalized the text and recommendations.
EVIDENCE REVIEW AND GRADING
All evidence related to WRA in searching four databases (PubMed, EBSCO, Cochrane Library, and Scopus) was included in this guideline. The comprehensive searches for evidence were performed through September 2012 for diagnostic studies and February 2014 for management studies to help ensure complete study capture. The search strategies retrieved a total of 10,598 articles that were screened, with all potentially appropriate study abstracts reviewed and evaluated against specified inclusion and exclusion criteria. Searches were supplemented with articles from personal files and reference reviews. A total of 497 articles were retrieved of which 157 met the inclusion criteria. Of those, 114 were included as high-or moderate-quality studies in evidence-based guideline development. The remaining 43 studies were deemed low-quality and excluded.
All included studies were scored for quality. Recommendations were graded from (A) to (C) in favor and against the specific diagnostic test or treatment, with (A) level recommendations having the highest quality body of literature. Quality evidence was developed into evidencebased recommendations. Expert consensus was employed for insufficient evidence (I) to develop consensus guidance. Recommendations and evidence tables were reviewed and amended by the multidisciplinary Panel. This guideline achieved 100% Panel agreement for all developed guidance.
COMMENTS AND MODIFICATION
Guidance was developed with sufficient detail to facilitate assessment of compliance (Institute of Medicine [IOM] ) and auditing/monitoring (Appraisal of Guidelines for Research and Evaluation). 24, 25 Alternative options to manage conditions are provided in other ACOEM guidelines when comparative trials are available. The only Appraisal of Guidelines for Research and Evaluation 25 and IOM criterion 24 not followed was incorporation of the views of the target population. In accordance with the IOM's Trustworthy Guidelines, this guideline underwent external peer review by four external reviewers, and subsequent revisions to the guidance, and detailed records of the peer-review processes have been kept, including responses to external peer reviewers. 24 This guideline is updated at least every 3 years or more frequently should evidence require it. All treatment recommendations are guidance based on synthesis of the evidence plus expert consensus. These recommendations are for practitioners, and decisions to adopt a particular course of action must be made by trained practitioners on the basis of available resources and the particular circumstances presented by the individual patient.
CLINICAL RECOMMENDATIONS
Sixteen diagnostic recommendations were formulated for diagnostic testing, of which 11 were ultimately recommended and five were not recommended ( Table  2 ). There were nine recommendations formulated for the management of WRA, of which five were recommended and four were not (Table 3) .
SPIROMETRY TESTING
Spirometry, performed alone or in conjunction with pre-and postbronchodilator testing, is an important component of the evaluation and management of persons with possible WRA. [26] [27] [28] [29] [30] [31] [32] Spirometry with bronchodilator administration has three distinct potential roles when WRA is a concern:
1. Determining whether asthma is present; 2. If asthma is present, helping inform the conclusion about whether the asthma is work related; and 3. Monitoring response to therapy and possible return to work. Spirometry with bronchodilator is not invasive, has few adverse effects, and is lowto-moderate cost and high in yield for complications and other respiratory problems. As its value lies in correlation with clinical information and observation, spirometry with bronchodilator is a recommended integral part of the evaluation of WRA.
PEAK EXPIRATORY FLOW RATES
Serial peak expiratory flow rate monitoring is moderately recommended (evidence level B) to diagnose WRA in patients already diagnosed with asthma by other methods. Six moderate-quality studies support the use of peak expiratory flow rate for the diagnosis of OA and WRA; however, peak expiratory flow rate is heavily dependent upon the worker's efforts and assumes worker honesty in performing and recording the test results.
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NONSPECIFIC BRONCHIAL PROVOCATION TESTING
Nonspecific bronchial provocation testing has been evaluated in quality studies that utilized methacholine, histamine, and mannitol as provocative testing agents. Four high-quality and 12 moderate-quality studies were used in formulating recommendations of nonspecific bronchial provocation testing as an investigational tool for the diagnoses of OA and WRA. [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] Nonspecific bronchial provocation testing is strongly recommended (evidence level A) to diagnose general asthma, and moderately recommended (evidence level B) to diagnose WRA. The Panel supports the American Thoracic Society's guideline for interpreting the methacholine dose that would result in a positive test. 58 
SPECIFIC IMMUNOLOGICAL TESTING
Specific immunological testing was evaluated separately for HMW and low molecular weight antigens. There were six highand 12 moderate-quality studies used in the formulation of recommendations for specific immunological testing. 50, 51, 57, [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] [72] [73] The Panel evaluated the difference between immunoglobulin E (IgE) and IgG tests. IgE testing for HMW antigens is strongly recommended (evidence level A) when specific testing reagents have been validated and are commercially available. Testing of IgG for HMW antigens is not recommended (evidence level C) for use as a diagnostic tool; however, this test may be efficacious as a marker for exposure to the antigen. IgE testing to low molecular weight antigens is not recommended (evidence level I). Skin-prick testing (SPT) was evaluated separately for HMW and low molecular weight allergens. There were eight high-and 12 moderate-quality studies used to formulate recommendations for SPT. 50,51,53,62,73 -88 SPT for HMW allergens is strongly recommended (evidence level A) for allergens that are commercially available and validated. Current commercially available validated extracts include some for natural rubber latex, wheat flour, Consider specific inhalation challenge testing (SICT) -highly specific use. (In the absence of ongoing suspect exposure, the relationship between airway reactivity and the suspect agent can only be confirmed with SIC; this may be the only absolute indication for performing a specific bronchial provocation challenge with a diisocyanate and is justified if the result will have an impact on future health and economic outcomes.) FIGURE 1. Diagnostic evaluation of occupational asthma with continuing exposure.
rye flour, grain dust, alpha-amylase, bovine danders, and other animal antigens. SPT to low molecular weight antigens is moderately recommended (evidence level B) for allergens that have a commercially available validated test including some available for reactive dyes, halogenated platinum salts, and trimellitic anhydride. All other SPT for allergens not specifically mentioned are not recommended (evidence level I).
SPECIFIC INHALATIONAL CHALLENGE TESTING
Specific inhalational challenge testing is often considered the gold standard test for diagnosing sensitizer-induced OA and is used when other methods have failed to establish the diagnosis. It is also used as a reference standard, as there is no other definitive diagnostic test. Four high-and 16 moderate-quality studies were used to formulate this recommendation. 11,42,46 -50,62,63,89 -99 However, specific inhalational challenge testing is highly technical and costly and has potential for severe adverse effects, including fatalities. Facilities must have the technological equipment and ability to control exposures, as well as monitor and resuscitate patients, and few such facilities exist. Thus, specific inhalational challenge testing is recommended only under highly select circumstances at appropriately equipped facilities that include direct medical supervision throughout the testing. The highly limited availability of facilities as well as adverse effects caused the Panel to reduce this recommendation from strongly recommended (evidence level A) to recommended (evidence level C).
NITRIC OXIDE TESTING
Nitric oxide testing-also known as fractional exhaled nitric oxide (FENO)-was evaluated as a diagnostic tool for all asthma including OA, and for selective monitoring of asthma treatment and progression. Two highand 20 moderate-quality studies were used to formulate recommendations for FENO.
45,100-119 FENO is not recommended to diagnose OA (evidence level I) as it cannot differentiate between asthma and other conditions such as eosinophilic inflammatory conditions. FENO is recommended (evidence level C) for diagnosis when more objective evidence is needed such as in litigated cases. FENO is recommended (evidence level B) in monitoring airway inflammation in patients with moderate and severe asthma as evidence indicates it correlates with the disease activity. 104, 107, 115 Additional guidance regarding criteria for clinically meaningful change and timing for FENO was abstracted from the evidence. 102, 118, [120] [121] [122] It is recommended that a change of 20% in the value is clinically significant and should be measured every 2 to 4 weeks while the treatment plan is being modified and finalized. 104, 122, 123 
NASAL LAVAGE TESTING
Eight moderate-quality studies were used in formulating recommendations for nasal lavage. 63,93,124 -129 Nasal lavage is recommended (evidence level C) for select workers with symptoms consistent with occupational upper airway allergy to specific allergens. The testing supports a diagnosis of occupational allergy, but Specific immunological testing (IgE) for workers with symptoms consistent with OA to certain HMW specific allergens and when standardized antigens and assay protocols exist-Strongly Recommended, Evidence (A) Specific immunological testing (IgG) as a diagnostic tool for select workers with symptoms consistent with OA to HMW specific allergens-Not Recommended, Evidence (C) Specific immunological testing (IgE) for workers with symptoms consistent with OA to low molecular weight specific allergens due to low sensitivity and specificity and lack of method validation-Not Recommended, Insufficient Evidence (I) Skin-prick testing Skin-prick testing for HMW allergens for select workers with symptoms consistent with OA to specific allergens and where validated, commercial skin testing extracts are available-Strongly Recommended, Evidence (A) Skin prick testing for low molecular weight allergens for select workers with symptoms consistent with OA to specific allergens, and where skin testing extracts are available-Moderately Recommended, Evidence (B) Skin-prick testing for allergens not covered above-Not Recommended, Insufficient Evidence (I) Specific inhalation challenge testing
Specific inhalation challenge testing for use in diagnosing WRA with latency for highly select cases, where the diagnosis of OA is highly suspected, but has not been established by less invasive means-Recommended, Evidence (C) Nitric oxide testing Nitric oxide testing for the diagnosis of OA, as it cannot differentiate between, eg, OA and other eosinophilic lung inflammatory conditions-Not Recommended, Insufficient Evidence (I) Exhaled nitric oxide testing for establishing a diagnosis of asthma when more objective evidence is needed such as in litigated cases-Recommended, Evidence (C) Exhaled nitric oxide testing for selective use in monitoring airway inflammation in patients with moderate and severe asthma-Moderately Recommended, Evidence (B) Nasal lavage testing Nasal lavage for select workers with symptoms consistent with occupational airways allergy to specific allergensRecommended, Evidence (C) Nasal lavage fluid analysis after challenge with the allergen for the diagnosis of OA-Not Recommended, Insufficient Evidence (I) IgE, immunoglobulin E; HMW, high molecular weight; OA, occupational asthma; WRA, work-related asthma.
other tests are required to establish a diagnosis of WRA; however, nasal lavage following nasal provocation testing is not recommended (evidence level I) for diagnosing OA.
MANAGEMENT OF WORK-RELATED ASTHMA
This guideline addresses management of WRA once it is diagnosed (Table  3) . There are 11 studies incorporated into this analysis, 1, 12, 43, 81, [130] [131] [132] [133] [134] [135] [136] [137] although none met high-or moderate-quality criteria. Thus, the panel reached the following conclusions regarding management of WRA on the basis of consensus.
Early diagnosis and early avoidance of further exposure, either by relocating the worker or substituting the hazard, offer the best chance of complete recovery. Patients with sensitizer-induced OA should be removed from further exposure to the causative agent in addition to providing other asthma management, 12 and it is recommended to educate all parties that complete avoidance of exposure to the identified antigen is preferred; however, complete removal is not always possible, for example, because of economic constraints of job change or loss, as well as patient preferences to continue in the same occupation. In that instance, the Panel recommends transfer to low levels of exposure to the asthmagen and frequent monitoring with questionnaire and spirometry surveillance to detect asthma deterioration. Reducing exposure to the causal agent in addition to providing immunotherapy and other asthma management, where applicable, depends on the asthmagen, level of exposure, severity of asthma (Table 4) , and the clinical judgment of the physician. If disease progression is documented, then removal from the exposure is strongly recommended. An exception is isocyanateinduced OA. This requires removing the worker from exposure, as there have been reported deaths in patients on medication and using respiratory protection.
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Studies have found that continued toluene diisocyanate exposure has been associated with increasingly persistent and severe respiratory symptoms. 137, [144] [145] [146] Personal protective equipment is not recommended as the only treatment option for managing OA.
Very few studies have specifically examined pharmacologic treatment in the management of WRA. The pharmacologic treatment of OA and WEA does not differ from the treatment of asthma that is not work related 12 ; it relies on a stepwise approach according to the severity of asthma and asthma control. Treatment for patients with a diagnosis of severe asthma has been recommended by the European Respiratory Society and the American Thoracic Society, but these recommendations did not exclude or specifically address OA or WEA. 147 The effectiveness of anti-asthma medications in patients who remain exposed to the causal agent has not been specifically addressed in previously published guidelines, 12, 131 or in the Agency for Healthcare Research and Quality systematic review. 1 
SUMMARY
This is the first WRA guideline to be published that is based on IOM-compliant criteria including systematic literature reviews, literature grading, expert panel consensus, and peer-review. 24 It is designed to be a resource for primary care providers, occupational medicine specialists, and pulmonary/allergy specialists who diagnose and manage occupationally related asthma.
RESEARCH RECOMMENDATIONS
Research into primary and secondary prevention is indicated to reduce the incidence of WRA. Also recommended is investigation to improve diagnostic methodology leading to earlier detection of sensitizerinduced OA, before progression to permanent asthma, and preventing further cases of sensitizer-induced OA. Management with pharmacological treatment options should be studied to identify treatments specific to OA and WEA, and to more specifically evaluate pharmacotherapy for different agents, for example, HMW versus low molecular weight antigens. 
APPLICABILITY AND IMPLEMENTATION ISSUES
The strengths of this guideline include the following: (1) comprehensive literature search; (2) a large database of studies from which to base recommendations; (3) the methodological literature abstraction and grading; and (4) the expert medical panel and expert external review processes. The main weaknesses stem from a general lack of high-quality diagnostic studies that are specific to WRA. Further rigorous study needs to be conducted in occupational settings for both diagnosis and management of WRA. Asthma severity is defined as follows: (1) Severe-having abnormal FEV 1 (<70%) and requiring use of high-dose inhaled corticosteroids and long-acting inhaled beta-agonists for symptom control.
(2) Moderately severe-having abnormal FEV 1 (<70%) and symptoms that are well-controlled with low dose inhaled corticosteroids and long-acting inhaled beta-agonists. (3) Low severity-having normal FEV 1 and symptom control by as-needed beta-agonist rescue or with low-intensity controller treatment such as low-dose inhaled corticosteroids, leukotriene receptor antagonists, or cromoglycates.
